Patents Examined by Jon M. Lockard
  • Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
    Patent number: 11235031
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 1, 2022
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Acetylcholine receptor-specific immunosuppressive compositions and methods of treatment of myasthenia gravis
    Patent number: 11235040
    Abstract: In one embodiment a vaccine composition comprises two or three AChR subunit constructs and an adjuvant. In some embodiments the AChR subunit construct is an AChR ?1 subunit construct, an AChR ?1 subunit construct, an AChR ? subunit construct, an AChR ? subunit construct, or an AChR ? subunit construct. In another embodiment, the invention provides a method of treating myasthenia gravis in a patient in need thereof, comprising administering a vaccine composition comprising one or more acetylcholine receptor subunit constructs selected from the group consisting of AChR ?1 subunit, AChR ?1 subunit, AChR ? subunit, AChR ? subunit, AChR ? subunit, a fragment thereof, and a combination thereof, and an adjuvant.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: February 1, 2022
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Jon Lindstrom, Jie Luo
  • Human monoclonal antibodies specific for FLT3 and uses thereof
    Patent number: 11236171
    Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 1, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien, Haiying Qin
  • Extended release of neuregulin for treating heart failure
    Patent number: 11179323
    Abstract: The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: November 23, 2021
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Nav1.9 target polypeptide, antibody and antibody fragment combined with same, and related pharmaceutical composition
    Patent number: 11174312
    Abstract: Provided is an antibody or a fragment thereof, which can be specifically bound to an S3-4 ring of a voltage sensor paddle of a domain III of voltage-gated sodium channel Nav1.9 ? sub-unit, and is able to inactivate a voltage sensor valve to keep sodium ions from entering nerve cells normally. Also provided is an epitope polypeptide specifically bound to the antibody or the fragment thereof, a pharmaceutical composition comprising the antibody or the fragment thereof, and a use of the antibody or the fragment thereof in preparing a drug for treating and diseases related to pains.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 16, 2021
    Assignee: POPULAS BIOPHARMACEUTICAL (WUHAN) LIMITED
    Inventor: Daichang Yang
  • Anti-metalloprotease antibody for diagnosis and treatment of cancers
    Patent number: 11160873
    Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: November 2, 2021
    Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd., Olivia Newton-John Cancer Research Institute
    Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
  • Anti-TREM-1 antibodies and uses thereof
    Patent number: 11155618
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 26, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • Dual PDGF/VEGF antagonists
    Patent number: 11155610
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 26, 2021
    Assignee: KODIAK SCIENCES INC.
    Inventors: Daniel Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
  • Patient-specific biomarkers of invasion in inflammatory bowel disease
    Patent number: 11150237
    Abstract: The present invention provides methods of detecting increased carcinoembryonic antigen-related cell adhesion molecule (CEACAM) protein expression in a biological sample from a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene. The invention also provides methods of treating or preventing inflammatory bowel disease (IBD) in a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 19, 2021
    Assignee: The Regents of the University of California
    Inventor: Declan McCole
  • Methods of treating viral infection
    Patent number: 11142795
    Abstract: Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 12, 2021
    Assignee: ACADEMIA SINICA
    Inventors: Shie-Liang Hsieh, Ya-Lang Huang, Tsung-Yu Tsai
  • Methods of screening compounds useful for treatment of a liver disease
    Patent number: 11141423
    Abstract: Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: October 12, 2021
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Lakshmi A. Devi, Raphael Rozenfeld
  • Antibodies and antibody fragments for binding to NAV1.9 polypeptides and methods for using same to treat pain-related disease
    Patent number: 11136382
    Abstract: The present invention provides an antibody or antibody fragment thereof for a targeted cytomembrane voltage-gated sodium channel ? subunit Nav1.9. The specific binding target is a S3-4 ring of a voltage sensor paddle of a domain II of the voltage-gated sodium channel ? subunit. The antibody or antibody fragment thereof is able to inactivate a voltage sensor valve, to make sodium ions unable to enter nerve cells normally, thereby achieving the effect of treating and relieving pains.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: October 5, 2021
    Assignee: POPULAS BIOPHARMACEUTICAL (WUHAN) LIMITED
    Inventor: Daichang Yang
  • Aflibercept formulations and uses thereof
    Patent number: 11135266
    Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: October 5, 2021
    Assignee: Just-Evotec Biologics, Inc.
    Inventors: Bruce A. Kerwin, Julee A. Floyd, Alison J. Gillespie, Christine C. Siska
  • Modified ligand-gated ion channels and methods of use
    Patent number: 11124554
    Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: September 21, 2021
    Assignee: Howard Hughes Medical Institute
    Inventors: Scott Sternson, Peter Lee, Christopher Magnus
  • Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides
    Patent number: 11103558
    Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 31, 2021
    Assignee: Duke University
    Inventor: Ashutosh Chilkoti
  • High concentration VEGF receptor fusion protein containing formulations
    Patent number: 11103552
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 31, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • Treatment of Hodgkin lymphoma using an anti-PD-1 antibody
    Patent number: 11083790
    Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 10, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventor: Benedetto Farsaci
  • Modified ligand-gated ion channels and methods of use
    Patent number: 11084853
    Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: August 10, 2021
    Assignee: Howard Hughes Medical Institute
    Inventors: Scott Sternson, Peter Lee, Christopher Magnus
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11084865
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: August 10, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11066458
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 20, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye